Automate Your Wheel Strategy on CBIO
With Tiblio's Option Bot, you can configure your own wheel strategy including CBIO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CBIO
- Rev/Share 178.8423
- Book/Share 162.4528
- PB 0.0799
- Debt/Equity 0.0118
- CurrentRatio 9.2098
- ROIC 0.0611
- MktCap 180325948.0
- FreeCF/Share 7.8512
- PFCF 26.7943
- PE 0.5279
- Debt/Assets 0.0104
- DivYield 0
- ROE 0.2525
- Rating
- Score
- Recommendation
- P/E Score
- DCF Score
- P/B Score
- D/E Score
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | CBIO | H.C. Wainwright | -- | Buy | -- | $25 | Aug. 11, 2025 |
| Initiation | CBIO | Wedbush | -- | Outperform | -- | $27 | July 14, 2025 |
| Initiation | CBIO | Stifel | -- | Buy | -- | $28 | June 25, 2025 |
News
About Catalyst Biosciences, Inc. (CBIO)
- IPO Date 2006-04-12
- Website https://www.catalystbiosciences.com
- Industry Biotechnology
- CEO Nassim Usman
- Employees 7
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The company also develops ProTUNE C3b/C4b degrader and ImmunoTUNE C3a/C5a degrader platforms designed to target other disorders of the complement or inflammatory pathways. It has a strategic research collaboration with Mosaic Biosciences, Inc.; and license and collaboration agreement with Biogen International GmbH. Catalyst Biosciences, Inc. was founded in 2002 and is headquartered in South San Francisco, California.